A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Guillermo Ortiz-RuizProtocol 018 Ertapenem Community-Acquired Pneumonia Study Group

Abstract

In a double-blind, multicenter trial, 502 patients hospitalized with community-acquired pneumonia were randomized to receive therapy with either ertapenem or ceftriaxone (for each, 1 g given intravenously once daily). After a minimum of 3 days, therapy could be switched to oral amoxicillin-clavulanate. The median duration of intravenously administered therapy for the 383 clinically evaluable patients was 4 days for both treatment groups; 345 patients (90.1%) had their treatment switched to orally administered therapy. Of the clinically evaluable patients, 168 (92.3%) in the ertapenem group and 183 (91.0%) in the ceftriaxone group had a favorable clinical response. Streptococcus pneumoniae was the most commonly isolated pathogen, and high cure rates were observed both for penicillin-susceptible and -nonsusceptible infections in the ertapenem group (28 [87.5%] of 32 patients versus 17 [100%] of 17 patients, respectively). Both treatment regimens were generally well tolerated; the most common drug-related adverse events reported were diarrhea (2.9% versus 2.7%) and nausea (0.8% versus 2.0%) in the ertapenem and ceftriaxone groups, respectively. These results suggest that ertapenem and ceftriaxone therapy have similar efficacy and ...Continue Reading

References

Jul 1, 1992·Diagnostic Microbiology and Infectious Disease·R J MangiV T Andriole
Dec 1, 1982·Controlled Clinical Trials·W C Blackwelder
Oct 1, 1993·Journal of the American Geriatrics Society·S L Phillips, J Branaman-Phillips
Jan 10, 1996·JAMA : the Journal of the American Medical Association·M J FineW N Kapoor
Oct 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S SegevS Pitlik
Nov 1, 1996·American Journal of Respiratory and Critical Care Medicine·R RiquelmeR Rodriguez-Roisin
Jan 23, 1997·The New England Journal of Medicine·M J FineW N Kapoor
Jun 13, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G BartlettT M File
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G BartlettM J Fine

❮ Previous
Next ❯

Citations

Nov 13, 2002·Pharmacoepidemiology and Drug Safety
Oct 22, 2003·Pathologie-biologie·Denis PiérardSabine Lauwers
Jun 8, 2002·Diagnostic Microbiology and Infectious Disease·Ian R FriedlandGail L Woods
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN Infectious Diseases Society of America
Jun 24, 2008·Surgical Infections·Samuel E WilsonMurray A Abramson
Jun 24, 2010·The Pediatric Infectious Disease Journal·Susan M Abdel-RahmanJeffrey L Blumer
Oct 18, 2002·Antimicrobial Agents and Chemotherapy·A K MajumdarJ D Rogers
Apr 24, 2003·Antimicrobial Agents and Chemotherapy·Donald G MussonJ Douglas Rogers
May 21, 2010·Journal of Inflammation·Maria SaroglouDemosthenes Bouros
Nov 10, 2009·Therapeutics and Clinical Risk Management·Fausto de Lalla
May 10, 2007·Drugs·George G ZhanelJames A Karlowsky
Apr 20, 2014·The Journal of Antimicrobial Chemotherapy·Joan P CannonShellee A Grim
May 20, 2005·Journal of Clinical Pharmacology·Olaf BurkhardtTobias Welte
Dec 23, 2003·Journal of the American Geriatrics Society·Gail L WoodsIan R Friedland
Nov 18, 2005·International Journal of Antimicrobial Agents·Eric NuermbergerWilliam R Bishai
Feb 26, 2013·Journal of Chemotherapy·Dominique BreilhEmmanuel Boselli
Aug 16, 2005·Clinica Chimica Acta; International Journal of Clinical Chemistry·Therese KoalVolkhard Kaever
Nov 24, 2004·Infectious Disease Clinics of North America·Thomas M File, Michael S Niederman
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Olaf BurkhardtTobias Welte
Jan 29, 2011·Scandinavian Journal of Infectious Diseases·Nazan DalgicSuleyman Pelit
Jun 25, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J M MurciaUNKNOWN SCAPE Study Group
Jan 13, 2005·The Annals of Pharmacotherapy·Arnold H SetoSteven S Guest
Aug 1, 2006·Médecine et maladies infectieuses·C Chidiac
Mar 11, 2005·Expert Review of Anti-infective Therapy·George G ZhanelDaryl J Hoban
Mar 4, 2017·The Kaohsiung Journal of Medical Sciences·Chi-Ren HuangYao-Chung Chuang
Oct 18, 2005·Drugs·Gillian M Keating, Caroline M Perry
Oct 22, 2003·Der Internist·T Welte
Jul 30, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Samuel DeshayesRenaud Verdon
Aug 19, 2003·Drugs·Monique CurranCaroline Perry
Jun 11, 2019·Expert Review of Anti-infective Therapy·João Paulo TellesFelipe Francisco Tuon
Mar 25, 2020·Antimicrobial Agents and Chemotherapy·Andrew AckermanThomas J Dilworth
Nov 26, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P S HicksM Motyl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

© 2022 Meta ULC. All rights reserved